| Literature DB >> 22496824 |
Michael Oster1, Eduard Murani, Cornelia C Metges, Siriluck Ponsuksili, Klaus Wimmers.
Abstract
BACKGROUND: In various animal models pregnancy diets have been shown to affect offspring phenotype. Indeed, the underlying programming of development is associated with modulations in birth weight, body composition, and continual diet-dependent modifications of offspring metabolism until adulthood, producing the hypothesis that the offspring's transcriptome is permanently altered depending on maternal diet. METHODOLOGY/PRINCIPALEntities:
Mesh:
Substances:
Year: 2012 PMID: 22496824 PMCID: PMC3322122 DOI: 10.1371/journal.pone.0034519
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Figure 1Number of probe sets showing a significantly altered abundance in muscle tissue.
The number of altered probe sets between adjacent developmental stages in AP or HP offspring are indicated at horizontal arrows; the number of commonly altered probe sets between stages in AP and HP offspring are indicated at intersections; the number of probe sets showing a different abundance between HP and AP offspring at the same developmental stage are indicated at vertical arrows; small arrows at the numbers indicate a higher or lower probe set abundance, respectively.
Figure 2Affected pathways in muscle tissue between developmental stages and diets.
Listed pathways between AP stages (white boxes) indicate shifts during development that are not found in HP offspring (black boxes) at the corresponding period. Pathways between HP stages indicate alterations that occur in HP offspring but not in AP offspring in the corresponding period. (Arrows between boxes show direction of comparison; small arrows indicate higher and lower transcript abundance, respectively. OXPHOS, oxidative phosphorylation; PLK, Polo-like kinase; mTOR, mammalian target of rapamycin; AMPK, AMP-activated protein kinase; IGF1, insulin-like growth factor 1; FA, Fatty acid; RAN, Ras-related nuclear protein).
Functional annotation of muscle transcripts showing altered abundance depending on the dietary group (HP vs. AP) within different developmental stages (Ingenuity Pathway Analysis).
| Developmental stage | Affected pathway | Expression |
| No. of genes involved | Genes involved in pathway |
| 94 dpc | Actin cytoskeleton signaling | up | 1.02*E-2 | 7 | ACTA1, CDC42, MSN, RDX, SSH2, TTN, VCL |
| G1/S checkpoint regulation | up | 2.48*E-2 | 3 | CDK6, E2F2, HDAC6 | |
| Cyclin and cell cycle regulation | up | 1.19*E-2 | 4 | CDK6, E2F2, HDAC6, PPP2R1A | |
| Organisation of filaments | up | 1.53*E-4 | 8 | COL1A1, COL1A2, COL5A1, LOX, MSN, NCK2, RDX, RHOB | |
| 1 dpn | Organisation of filaments | up | 1.03*E-7 | 10 | AKAP2, COL1A1, COL1A2, COL5A1, COL5A2, DCN, FN1, LOX, P4HA1, SERPINH1 |
| 28 dpn | - | - | - | - | - |
| 188 dpn | - | - | - | - | - |
Up and down indicate higher and lower abundance in HP compared to AP, respectively. P-value: significance of association between dataset and IP-pathways; Fischer's exact test.
Functional annotation of muscle transcripts showing altered abundance between two developmental stages within either dietary group HP or AP (Ingenuity Pathway Analysis).
| Developmental comparison | Diet | Affected pathway | Expression |
| No. of genes involved | Genes involved in pathway |
| 94 dpc vs. 1 dpn | AP | RAN signaling | up | 8.64*E-3 | 3 | CSE1L, IPO5, KPNA1 |
| AP | IGF1 signaling | up | 3.97*E-2 | 6 | CSNK2A1, MAP2K1, PRKAR2A, RAF1, SOS1, YWHAG | |
| AP | Organisation of filaments | down | 1.26*E-2 | 13 | B4GALT7, BGN, CNP, COL1A2, COL2A1, COL5A1, EVL, FGF2, FNBP1, LOX, MTSS1, TGFB1, TNXB | |
| HP | Purine metabolism | up | 3.19*E-4 | 21 | ADCY3, ATP13A2, ATP6V0B, BCKDHA, BCKDHB, ENTPD4, GMPR, ITPA, MAD2L2, NME1, NME2, NME3, NUDT2, POLD4, POLR1C, POLR2G, POLR2I, POLR2L, PSMC1, RRM2B, RUVBL1 | |
| HP | Pyrimidine metabolism | up | 1.19*E-5 | 16 | ENTPD4, ITPA, MAD2L2, NME1, NME2, NME3, NUDT2, POLD4, POLR1C, POLR2G, POLR2I, POLR2L, RPUSD1, RPUSD2, RPUSD4, RRM2B | |
| HP | Oxidative phosphorylation | up | 1.24*E-2 | 10 | ATP6AP1, ATP6V0B, ATP6V0E2, COX6B1, NDUFA8, NDUFB7, NDUFB9, NDUFS3, RPUSD1, TNNI2 | |
| HP | Synthesis and degradation of ketone bodies | up | 4.43*E-3 | 3 | ACAA1, ACAT2, BDH1 | |
| HP | Glucocorticoid receptor signaling | down | 1.27*E-4 | 24 | CCL2, FOS, GTF2E2, GTF2H3, JUN, NCOA1, NCOA2, NCOA3, NCOR1, PIK3C3, PIK3R3, POLR2D, PPP3CB, PRKACB, RRAS2, SERPINE1, SHC1, SMAD3, STAT1, SUMO1, TBP, TGFB2, TGFBR2, TRAF6 | |
| HP | Cyclin and cell cycle regulation | down | 8.09*E-5 | 12 | ATR, CCNA2, CDKN1B, E2F2, HDAC3, HDAC6, PPP2CB, PPP2R1A, PPP2R1B, PPP2R5E, RB1, TGFB2 | |
| HP | G1/S checkpoint regulation | down | 1.86*E-3 | 8 | ATR, CDKN1B, E2F2, HDAC3, HDAC6, RB1, SMAD3, TGFB2 | |
| HP | Growth hormone signaling | down | 1,71*E-3 | 9 | FOS, GHR, IGF1, IGFBP3, PIK3C3, PIK3R3, RPS6KA3, RPS6KA5, STAT1 | |
| HP | Mitotic roles of Polo-like kinase | down | 3.51*E-2 | 6 | CDC27, PLK4, PPP2CB, PPP2R1A, PPP2R1B, PPP2R5E | |
| HP | IGF1 signaling | down | 8.90*E-5 | 13 | FOS, IGF1, IGFBP3, IGFBP5, JUN, PIK3C3, PIK3R3, PRKACB, PTPN11, RRAS2, SHC1, YWHAB, YWHAE | |
| 1 dpn vs. 28 dpn | AP | Purine metabolism | up | 7.50*E-3 | 21 | ACIN1, ATP11B, ATP13A2, ATP5G2, ATP6V0B, CHRAC1, CILP, DDX19B, DGUOK, NME3, PDE2A, PDE5A, POLG, POLR2D, POLR2E, POLR2F, POLR2J, POLR3K, PRPSAP2, PSMC5, RFC3 |
| AP | Pyrimidine metabolism | up | 5.95*E-3 | 13 | CHRAC1, CTPS2, NME3, POLG, POLR2D, POLR2E, POLR2F, POLR2J, POLR3K, RFC3, RPUSD1, RPUSD4, UCK1 | |
| AP | Organisation of filaments | up | 5.74*E-3 | 12 | AKAP2, COL1A1, COL1A2, COL5A2, CRYAA, DBN1, DCN, FN1, FNBP1, PDLIM3D, SERPINH1, TGFB1 | |
| AP | Fatty acid elongation in mitochondria | down | 4.39*E-4 | 5 | ACAA2, AUH, HADH, HSD17B4, PECR | |
| AP | RAN signaling | down | 2.49*E-2 | 3 | IPO5, RAN, XPO1 | |
| AP | Oxidative phosphorylation | down | 1.54*E-9 | 25 | ATP5B, ATP5C1, ATP5F1, ATP5J, ATP6V1A, ATP6V1B2, ATP6V1C1, ATP6V1H, COX15, COX17, COX6C, COX7C, NDUFA1, NDUFA9, NDUFAB1, NDUFB1, NDUFB3, NDUFB5,NDUFC1, NDUFS2, NDUFV2, PPA2, SDHA, UQCR11, UQCRB | |
| HP | G2/M DNA damage checkpoint regulation | up | 2.63*E-4 | 8 | ATR, CCNB1, CCNB2, PTPMT1, RPRM, WEE1, YWHAE, YWHAG | |
| HP | Mitotic roles of Polo-like kinase | up | 4.95*E-4 | 9 | ANAPC1, ANAPC5, CCNB1, CCNB2, PLK4, PPP2R3A, PTTG1, STAG2, WEE1 | |
| HP | Oxidative phosphorylation | up | 2.23*E-3 | 14 | ATP5A1, ATP5O, ATP6V1A, ATP6V1E1, COX7B, FAM63B, IP6K2, NDUFB6, NDUFS1, NDUFS4, NDUFV2, PPA1, PPA2, UHRF1BP1 | |
| HP | RAN signaling | up | 2.88*E-3 | 4 | CSE1L, IPO5, TNPO1, XPO1 | |
| HP | Organisation of filaments | down | 1.46*E-3 | 16 | ARHGEF2, BGN, COL1A1, COL1A2, COL2A1, COL5A1, DBN1, DCN, EVL, FAT1, FES, LOX, MARK4, NUMA1, PPP1R9AD, SIRPA | |
| 28 dpn vs. 188 dpn | AP | AMPK signaling | up | 1.10*E-2 | 11 | PIK3R1, PPP2CA, PPP2CB, PPP2R2A, PPP2R5A, PPP2R5E, PRKAA1, PRKAA2, PRKAB2, PRKACB, SMARCA2 |
| AP | Mitotic roles of Polo-like kinase | up | 1.56*E-3 | 8 | ANAPC11, HSP90AA1, PPP2CA, PPP2CB, PPP2R2A, PPP2R5A, PPP2R5E, STAG2 | |
| AP | mTOR signaling | up | 9.70*E-4 | 14 | EIF3A, EIF4B, NAPEPLD, PIK3R1, PPP2CA, PPP2CB, PPP2R2A, PPP2R5A, PPP2R5E, PRKAA1, PRKAA2, PRKAB2, RHOQ, RICTOR | |
| AP | Cyclin and cell cycle regulation | up | 6.40*E-4 | 10 | ATR, GSK3B, HDAC2, PPP2CA, PPP2CB, PPP2R2A, PPP2R5A, PPP2R5E, RAF1, TGFB2 | |
| HP | Purine metabolism | up | 8.46*E-3 | 20 | AMPD3, ATF7IP, ATP6V0E1, ATP6V1G2, DDX19B, EIF2AK4, MAD2L2, MPP1, NME6, NT5C3, POLG, POLR1A, POLR2C, POLR2F, PPAT, PSMC1, PSMC3, PSMC5, RFC3, VCP | |
| HP | Pyrimidine metabolism | up | 2.36*E-2 | 11 | CMPK1, EIF2AK4, MAD2L2, NME6, NT5C3, NXN, POLG, POLR1A, POLR2C, POLR2F, RFC3 | |
| HP | Glucocorticoid receptor signaling | up | 2.13*E-2 | 16 | A2M, AGT, CXCL3, EP300, HSP90AA1, MAP3K14, NCOA2, NCOR2, NR3C1, PIK3C3, POLR2C, POLR2F, SMAD3, STAT5B, TAT, TSC22D3 | |
| HP | Oxidative phosphorylation | down | 1.35*E-3 | 14 | COX15, COX6A1, COX7C, IP6K2, NDUFA2, NDUFB3, NDUFB5, NDUFB6, NDUFB10, NDUFS3, NDUFS4, NDUFS6, PPA2, UQCRB | |
| HP | Mitotic roles of Polo-like kinase | down | 2.30*E-2 | 6 | CCNB2, CDK1, PLK4, PRC1, PTTG1, WEE1 | |
| HP | G2/M DNA damage checkpoint regulation | down | 2.25*E-2 | 5 | CCNB2, CDK1, CKS1B, WEE1, YWHAZ |
Up and down indicate higher and lower abundance in later compared to earlier stages, respectively. P-value: significance of association between dataset and IP-pathways; Fischer's exact test.
Figure 3Experimental design.
Fetuses and offspring of divergently fed sows were collected at 4 developmental stages. Fetuses were derived from 3 sows per dietary group. Offspring were full sibs of six litters per dietary group collected at 3 consecutive postnatal stages; HP = high protein, CP = crude protein, AP = adequate protein.